These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28098593)

  • 1. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
    Koopal C; Marais AD; Visseren FL
    Curr Opin Endocrinol Diabetes Obes; 2017 Apr; 24(2):133-139. PubMed ID: 28098593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.
    Koopal C; Marais AD; Westerink J; Visseren FL
    J Clin Lipidol; 2017; 11(1):12-23.e1. PubMed ID: 28391878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and laboratory investigation of dysbetalipoproteinemia.
    Boot CS; Luvai A; Neely RDG
    Crit Rev Clin Lab Sci; 2020 Nov; 57(7):458-469. PubMed ID: 32255405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.
    Boot CS; Middling E; Allen J; Neely RDG
    Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.
    Marais D
    Curr Opin Lipidol; 2015 Aug; 26(4):292-7. PubMed ID: 26103610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis.
    Havel RJ
    Med Clin North Am; 1982 Mar; 66(2):441-54. PubMed ID: 7040846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
    Smelt AH; de Beer F
    Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
    Heidemann BE; Koopal C; Baass A; Defesche JC; Zuurbier L; Mulder MT; Roeters van Lennep JE; Riksen NP; Boot C; Marais AD; Visseren FLJ
    Clin Genet; 2022 Oct; 102(4):253-261. PubMed ID: 35781703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary recommendations for dysbetalipoproteinemia: A need for better evidence.
    Paquette M; Blais C; Fortin A; Bernard S; Baass A
    J Clin Lipidol; 2023; 17(4):549-556. PubMed ID: 37268489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study.
    Blokhina AV; Ershova AI; Kiseleva AV; Sotnikova EA; Zharikova AA; Zaicenoka M; Vyatkin YV; Ramensky VE; Kutsenko VA; Shalnova SA; Meshkov AN; Drapkina OM
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia.
    Paquette M; Bernard S; Paré G; Baass A
    J Clin Lipidol; 2020; 14(1):46-52. PubMed ID: 31959563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling.
    Corsetti JP; Love TM; Sparks CE; Bakker SJL; Dullaart RPF
    Clin Biochem; 2018 Sep; 59():31-36. PubMed ID: 29928902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia.
    Heidemann BE; Koopal C; Roeters van Lennep JE; Stroes ESG; Riksen NP; Mulder MT; -van der Zee LCVV; Blackhurst DM; Marais AD; Visseren FLJ
    J Clin Lipidol; 2023; 17(1):112-123. PubMed ID: 36384662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
    Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial dysbetalipoproteinemia: a potentially fatal disorder.
    Bari AU; Hashim R; Rahman SB; Hussain M
    J Coll Physicians Surg Pak; 2008 Aug; 18(8):506-8. PubMed ID: 18798589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.
    Kei A; Miltiadous G; Bairaktari E; Hadjivassiliou M; Cariolou M; Elisaf M
    World J Clin Cases; 2015 Apr; 3(4):371-6. PubMed ID: 25879010
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.